Mechanisms underlying the antifibrotic properties of noninhibitory PAI-1 (PAI-1R) in experimental nephritis

American Journal of Physiology - Renal Physiology

Volumn 297, Issue 4, 2009, Pages

  Huang, Yufeng ^a   Border, Wayne A ^a   Lawrence, Daniel A ^b   Noble, Nancy A ^a  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

ECM; PAI 1 mutants; Renal fibrosis; Vitronectin

Indexed keywords

ANTIFIBROTIC AGENT; COLLAGEN TYPE 1; FIBRONECTIN; MESSENGER RNA; MUTANT PROTEIN; PLASMIN; PLASMINOGEN ACTIVATOR INHIBITOR 1; PLASMINOGEN ACTIVATOR INHIBITOR 1AK; PLASMINOGEN ACTIVATOR INHIBITOR 1R; PROTEIN 14 1B; PROTEINASE; PROTEINASE INHIBITOR; RECOMBINANT PROTEIN; TRANSFORMING GROWTH FACTOR BETA1; UNCLASSIFIED DRUG; VITRONECTIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; CELL DEGENERATION; CELL INFILTRATION; CELL LEVEL; CONTROLLED STUDY; DISEASE MODEL; DOSE RESPONSE; EXTRACELLULAR MATRIX; GLOMERULUS; HALF LIFE TIME; IMMUNOFLUORESCENCE TEST; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATORY CELL; MALE; MESANGIUM CELL; MOLECULAR MECHANICS; NEPHRITIS; NONHUMAN; PERIODIC ACID SCHIFF STAIN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN BLOOD LEVEL; PROTEIN DEGRADATION; PROTEIN FUNCTION; PROTEIN STABILITY; PROTEIN SYNTHESIS; RAT; THERAPY; THERAPY EFFECT; TIME; URINARY EXCRETION; WILD TYPE;

EID: 70349644472     PISSN: 1931857X     EISSN: 15221466     Source Type: Journal    
DOI: 10.1152/ajprenal.00024.2009     Document Type: Article

References (42)

1. Baricos WH, Cortez SL, El-Dahr SS, Schnaper HW. ECM degradation by cultured human mesangial cells is mediated by a PA/plasmin/MMP-2 cascade. Kidney Int 47: 1039-1047, 1995.
2. Baricos WH, Reed JC, Cortez SL. Extracellular matrix degradation by cultured mesangial cells: mediators and modulators. Exp Biol Med (Maywood) 228: 1018-1022, 2003. (Pubitemid 37222169)
3. Berkenpas MB, Lawrence DA, Ginsburg D. Molecular evolution of plasminogen activator inhibitor-1 functional stability. EMBO J 14: 2969-2977, 1995.
4. Deng G, Curriden SA, Wang S, Rosenberg S, Loskutoff DJ. Is plasminogen activator inhibitor-1 the molecular switch that governs urokinase receptor-mediated cell adhesion and release? J Cell Biol 134: 1563-1571, 1996. (Pubitemid 26318027)
5. Deng G, Royle G, Seiffert D, Loskutoff DJ. The PAI-1/vitronectin interaction: two cats in a bag? Thromb Haemost 74: 66-70, 1995.
6. Deng G, Royle G, Wang S, Crain K, Loskutoff DJ. Structural and functional analysis of the plasminogen activator inhibitor-1 binding motif in the somatomedin B domain of vitronectin. J Biol Chem 271: 12716-12723, 1996. (Pubitemid 26175840)
7. Eddy AA, Fogo AB. Plasminogen activator inhibitor-1 in chronic kidney disease: evidence and mechanisms of action. J Am Soc Nephrol 17: 2999-3012, 2006.
8. Eitzman DT, McCoy RD, Zheng X, Fay WP, Shen T, Ginsburg D, Simon RH. Bleomycin-induced pulmonary fibrosis in transgenic mice that either lack or overexpress the murine plasminogen activator inhibitor-1 gene. J Clin Invest 97: 232-237, 1996. (Pubitemid 26021713)
9. Furuichi K, Kaneko S, Wada T. Chemokine/chemokine receptor-mediated inflammation regulates pathologic changes from acute kidney injury to chronic kidney disease. Clin Exp Nephrol 13: 9-14, 2009.
10. Ghee JY, Han DH, Song HK, Kim WY, Kim SH, Yoon HE, Choi BS, Kim YS, Kim J, Yang CW. The role of macrophage in the pathogenesis of chronic cyclosporine-induced nephropathy. Nephrol Dial Transplant 23: 4061-4069, 2008.
11. Gong R, Rifai A, Tolbert EM, Centracchio JN, Dworkin LD. Hepatocyte growth factor modulates matrix metalloproteinases and plasminogen activator/plasmin proteolytic pathways in progressive renal interstitial fibrosis. J Am Soc Nephrol 14: 3047-3060, 2003. (Pubitemid 37509283)
12. Haraguchi M, Border WA, Huang Y, Noble NA. t-PA promotes glomerular plasmin generation and matrix degradation in experimental glomerulonephritis. Kidney Int 59: 2146-2155, 2001. (Pubitemid 32467606)
13. Hattori N, Degen JL, Sisson TH, Liu H, Moore BB, Pandrangi RG, Simon RH, Drew AF. Bleomycin-induced pulmonary fibrosis in fibrinogen- null mice. J Clin Invest 106: 1341-1350, 2000.
14. Hekman CM, Loskutoff DJ. Endothelialc cells produce a latent inhibitor of plasminogen activators that can be activated by denaturants. J Biol Chem 260: 11581-11887, 1985.
15. Huang Y, Border WA, Lawrence DA, Noble NA. Noninhibitory PAI-1 enhances plasmin-mediated matrix degradation both in vitro and in experimental nephritis. Kidney Int 70: 515-522, 2006. (Pubitemid 44141578)
16. Huang Y, Border WA, Yu L, Zhang J, Lawrence DA, Noble NA. A PAI-1 mutant, PAI-1R, slows progression of diabetic nephropathy. J Am Soc Nephrol 19: 329-338, 2008. (Pubitemid 351240654)
17. Huang Y, Haraguchi M, Lawrence DA, Border WA, Yu L, Noble NA. A mutant, noninhibitory plasminogen activator inhibitor type 1 decreases matrix accumulation in experimental glomerulonephritis. J Clin Invest 112: 379-388, 2003. (Pubitemid 38063766)
18. Huang Y, Noble NA. PAI-1 as a target in kidney disease. Curr Drug Targets 8: 1007-1015, 2007.
19. Jensen JK, Gettins PG. High-resolution structure of the stable plasminogen activator inhibitor type-1 variant 14-1B in its proteinase-cleaved form: a new tool for detailed interaction studies and modeling. Protein Sci 17: 1844-1849, 2008.
20. Kjoller L, Kanse SM, Kirkegaard T, Rodenburg KW, Ronne E, Goodman SL, Preissner KT, Ossowski L, Andreasen PA. Plasminogen activator inhibitor-1 represses integrin- and vitronectin-mediated cell migration independently of its function as an inhibitor of plasminogen activation. Exp Cell Res 232: 420-429, 1997. (Pubitemid 27194058)
21. Kvassman JO, Shore JD. Purification of human plasminogen activator inhibitor (PAI-1) from Escherichia coli and separation of its active and latent forms by hydrophobic chromography. Fibrinolysis 9: 215-221, 1995.
22. Laug WE, Weinblatt ME, Jones PA. Endothelial cells degrade extracellular matrix proteins produced in vitro. Thromb Haemost 54: 498-502, 1985. (Pubitemid 16255681)
23. Lawrence DA, Palaniappan S, Stefansson S, Olson ST, Francis-Chmura AM, Shore JD, Ginsburg D. Characterization of the binding of different conformational forms of plasminogen activator inhibitor-1 to vitronectin. J Biol Chem 272: 7676-7680, 1997.
24. Lawrence DA, Berkenpas MB, Palaniappan S, Ginsburg D. Localization of vitronectin binding domain in plasminogen activator inhibitor-1. J Biol Chem 269: 15223-15228, 1994. (Pubitemid 24198370)
25. Lijnen HR, Collen D. Matrix metalloproteinase system deficiencies and matrix degradation. Thromb Haemost 82: 837-845, 1999.
26. Liotta LA, Goldfarb RH, Brundage R, Siegal GP, Terranova V, Garbisa S. Effect of plasminogen activator (urokinase), plasmin, and thrombin on glycoprotein and collagenous components of basement membrane. Cancer Res 41: 4629-4636, 1981. (Pubitemid 12201384)
27. Mackay AR, Corbitt RH, Hartzler JL, Thorgeirsson UP. Basement membrane type IV collagen degradation: evidence for the involvement of a proteolytic cascade independent of metalloproteinases. Cancer Res 50: 5997-6001, 1990.
28. McLennan SV, Fisher E, Martell SY, Death AK, Williams P, Lyons JG, Yue DK. Effects of glucose on matrix metalloproteinase and plasmin activities in mesangial cells: possible role in diabetic nephropathy. Kidney Int Suppl 77: S81-S87, 2000. (Pubitemid 30681195)
29. Mochan E, Keler T. Plasmin degradation of cartilage proteoglycan. Biochim Biophys Acta 800: 312-315, 1984.
30. Mottonen J, Strand A, Symersky J, Sweet RM, Danley DE, Geoghegan KF, Gerard RD, Goldsmith EJ. Structural basis of latency in plasminogen activator inhibitor-1. Nature 355: 270-273, 1992.
31. Nicholas SB, Aguiniga E, Ren Y, Kim J, Wong J, Govindarajan N, Noda M, Wang W, Kawano Y, Collins A, Hsueh WA. Plasminogen activator inhibitor-1 deficiency retards diabetic nephropathy. Kidney Int 67: 1297-1307, 2005. (Pubitemid 40463106)
32. Okada H, Watanabe Y, Kikuta T, Kobayashi T, Kanno Y, Sugaya T, Suzuki H. Bradykinin decreases plasminogen activator inhibitor-1 expression and facilitates matrix degradation in the renal tubulointerstitium under angiotensin-converting enzyme blockade. J Am Soc Nephrol 15: 2404-2413, 2004. (Pubitemid 39159340)
33. Seiffert D, Loskutoff DJ. Evidence that type 1 plasminogen activator inhibitor binds to the somatomedin B domain of vitronectin. J Biol Chem 266: 2824-2830, 1991. (Pubitemid 21909141)
34. Seiffert D, Loskutoff DJ. Kinetic analysis of the interaction between type 1 plasminogen activator inhibitor and vitronectin and evidence that the bovine inhibitor binds to a thrombin-derived amino-terminal fragment of bovine vitronectin. Biochim Biophys Acta 1078: 23-30, 1991.
35. Stefansson S, Lawrence DA. The serpin PAI-1 inhibits cell migration by blocking integrin alpha V beta 3 binding to vitronectin. Nature 383: 441-443, 1996. (Pubitemid 26330833)
36. Stefansson S, Muhammad S, Cheng XF, Battey FD, Strickland DK, Lawrence DA. Plasminogen activator inhibitor-1 contains a cryptic high affinity binding site for the low density lipoprotein receptor-related protein. J Biol Chem 273: 6358-6366, 1998. (Pubitemid 28144727)
37. Stefansson S, Petitclerc E, Wong MK, McMahon GA, Brooks PC, Lawrence DA. Inhibition of angiogenesis in vivo by plasminogen activator inhibitor-1. J Biol Chem 276: 8135-8141, 2001. (Pubitemid 37385618)
38. Wilkins-Port CE, Ye Q, Mazurkiewicz JE, Higgins PJ. TGF-beta1 + EGF-initiated invasive potential in transformed human keratinocytes is coupled to a plasmin/MMP-10/MMP-1-dependent collagen remodeling axis: role for PAI-1. Cancer Res 69: 4081-4091, 2009.
39. Xu Z, Balsara RD, Gorlatova NV, Lawrence DA, Castellino FJ, Ploplis VA. Conservation of critical functional domains in murine plasminogen activator inhibitor-1. J Biol Chem 279: 17914-17920, 2004. (Pubitemid 38560560)
40. Zhang G, Kernan KA, Collins SJ, Cai X, Lopez-Guisa JM, Degen JL, Shvil Y, Eddy AA. Plasmin(ogen) promotes renal interstitial fibrosis by promoting epithelial-to-mesenchymal transition: role of plasmin-activated signals. J Am Soc Nephrol 18: 846-859, 2007. (Pubitemid 46434501)
41. Zheng X, Saunders TL, Camper SA, Samuelson LC, Ginsburg D. Vitronectin is not essential for normal mammalian development and fertility. Proc Natl Acad Sci USA 92: 12426-12430, 1995. (Pubitemid 26014082)
42. Zhou A, Huntington JA, Pannu NS, Carrell RW, Read RJ. How vitronectin binds PAI-1 to modulate fibrinolysis and cell migration. Nat Struct Biol 10: 541-544, 2003. (Pubitemid 36792905)